QUICK ANSWER: Clinical research demonstrates it is highly effective at reducing visceral fat by stimulating the body’s own growth hormone production. It is FDA-approved specifically for this purpose, with multiple randomised controlled trials confirming significant abdominal fat reduction.
Tesamorelin is one of the most clinically researched peptides in the field of metabolic medicine, and the question of whether it is good for fat loss is one that an expanding number of researchers, clinicians, and scientifically curious individuals are searching for answers to. Unlike many compounds that circulate within research communities without a formal evidence base, Tesamorelin carries something rare in this space: a body of peer-reviewed clinical trial data rigorous enough to support regulatory approval by the United States Food and Drug Administration. That approval — granted in 2010 under the brand name Egrifta — was specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, a condition characterised by pathological visceral fat accumulation driven by growth hormone deficiency.
🔗 Related Reading: For a comprehensive overview of Tesamorelin research, mechanisms, UK sourcing, and safety data, see our Tesamorelin UK: Complete Research Guide (2026).
